Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.
Effect of ResQFoam to Slow or Stop Severe Internal Bleeding in Trauma Patients
Trauma is the leading cause of death in people younger than 45 years. Unfortunately, 40-50% of severely injured patients with internal bleeding die, even after reaching the hospital. This clinical study is about whether ResQFoam can help slow or stop severe internal bleeding in the abdomen (belly area) while the patient is being brought in for surgery. ResQFoam is a device that injects a liquid foam into the abdomen. The foam expands and forms a seal around the bleeding wounds, reducing blood loss.
Not yet recruiting | Hemorrhagic Shock | Not Multisite
Tracking the Risk for Alzheimer’s Disease using the APT Webstudy
The Alzheimer Prevention Trials (APT) Webstudy is designed to accelerate enrollment into Alzheimer’s clinical trials by identifying and tracking individuals online, who may be at higher risk for developing Alzheimer’s. The Alzheimer’s Association estimates that 5.5 million Americans age 65 and older are currently living with Alzheimer’s dementia. It’s believed these numbers will increase by almost 30% to over 7 million people by 2025, where it’s the only top 10 cause of death that cannot be prevented, cured, or even slowed. The APT Webstudy is open to anyone over the age of 50. The goal of the APT Webstudy is to develop an online group of individuals who will allow their memory and thinking test scores to be tracked over time. Participants will have the opportunity to take online tests to assess their memory and thinking skills, gain access to their scores, and be notified of opportunities for in-person assessments and clinical trials aimed at preventing dementia. These in-person visits will be offered through the closest clinical site to participants.
Effect of Corneal Preservation Time on Long-Term Graft Success
When the donor cornea is removed from the person who died, it is prepared for
transplantation by an eye bank. The donor cornea is placed into a liquid that helps
preserve the cornea until it is transplanted. The Food and Drug Administration (FDA) has
approved storage of the cornea in this liquid for up to 14 days before the transplant. The
purpose of this study is to see if the length of time the donor cornea is kept in the
preservation liquid before the transplant affects the likelihood of the transplant being
successful. We will follow participants for 3 years after transplant to see if there are any
differences in transplant success or in the number of transplanted endothelial cells (the
layer of cells that line the undersurface of the cornea) on the corneas that were preserved
for 7 days or less compared to those preserved between 8 and 14 days. We have no reason to
believe that there is any greater risk for transplant failure with either preservation time
group.
Powered by
SC CTSI